Twelve-month clinical results from the new cobalt-chromium sirolimus-eluting dedicated bifurcation stent BiOSS LIM C Registry
Introduction Percutaneous coronary interventions (PCI) in bifurcations are still challenging and are associated with higher risks of periprocedural complications as well as restenosis and stent thrombosis. The aim of this paper was to summarize 12 months of clinical results of the prospective, first...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2020-02-01
|
| Series: | Archives of Medical Science |
| Subjects: | |
| Online Access: | https://www.archivesofmedicalscience.com/Twelve-month-clinical-results-from-the-new-cobalt-chromium-sirolimus-eluting-dedicated,111580,0,2.html |
| _version_ | 1797435372353880064 |
|---|---|
| author | Robert J. Gil Adam Kern Tomasz Pawłowski Jacek Bil |
| author_facet | Robert J. Gil Adam Kern Tomasz Pawłowski Jacek Bil |
| author_sort | Robert J. Gil |
| collection | DOAJ |
| description | Introduction
Percutaneous coronary interventions (PCI) in bifurcations are still challenging and are associated with higher risks of periprocedural complications as well as restenosis and stent thrombosis. The aim of this paper was to summarize 12 months of clinical results of the prospective, first-in-man registry assessing the BiOSS LIM C stent (Balton, Poland).
Material and methods
In the prospective two-center registry we enrolled patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and stable coronary artery disease. Provisional T-stenting was the default treatment strategy. The primary endpoint was defined as the rate of cardiac death, myocardial infarction (MI) and clinically driven target lesion revascularization (TLR) in 12-month follow-up.
Results
The study population consisted of 95 patients (mean age: 66.8 ±9.8 years, 17.9% were females). A BiOSS LIM C stent was implanted in the left main (LM) in 53 (55.8%) cases. There were 25.2% of patients with NSTE-ACS, 33.7% with diabetes, 90.5% with hypertension, and 53.7% had previous MI. The device success rate was 100%. An additional regular drug-eluting stent was deployed in the side branch in 18.9% of cases. Proximal optimization technique and final kissing balloon (FKB) technique were used in 53.7% and 30.5% of cases, respectively. MI type 4a was registered in 4 (4.2%) cases. At 12 months the MACE rate was 9.5%, cardiac death 1.1%, MI 2.1% and clinically driven TLR 6.3%. All incidents, apart from one TLR, appeared in the LM subgroup.
Conclusions
Our registry might suggest that PCI using the BiOSS LIM C in coronary bifurcations is feasible and might be an option for percutaneous revascularization. |
| first_indexed | 2024-03-09T10:47:16Z |
| format | Article |
| id | doaj.art-40b775a373fb4d2492e80ae19568d6cf |
| institution | Directory Open Access Journal |
| issn | 1734-1922 1896-9151 |
| language | English |
| last_indexed | 2024-03-09T10:47:16Z |
| publishDate | 2020-02-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Archives of Medical Science |
| spelling | doaj.art-40b775a373fb4d2492e80ae19568d6cf2023-12-01T09:52:58ZengTermedia Publishing HouseArchives of Medical Science1734-19221896-91512020-02-0119232433010.5114/aoms.2020.92974111580Twelve-month clinical results from the new cobalt-chromium sirolimus-eluting dedicated bifurcation stent BiOSS LIM C RegistryRobert J. Gil0Adam Kern1Tomasz Pawłowski2Jacek Bil3Department of Invasive Cardiology, Centre of Postgraduate Medical Education, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, PolandDepartment of Cardiology and Cardiosurgery, Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, PolandDepartment of Invasive Cardiology, Centre of Postgraduate Medical Education, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, PolandDepartment of Invasive Cardiology, Centre of Postgraduate Medical Education, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, PolandIntroduction Percutaneous coronary interventions (PCI) in bifurcations are still challenging and are associated with higher risks of periprocedural complications as well as restenosis and stent thrombosis. The aim of this paper was to summarize 12 months of clinical results of the prospective, first-in-man registry assessing the BiOSS LIM C stent (Balton, Poland). Material and methods In the prospective two-center registry we enrolled patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and stable coronary artery disease. Provisional T-stenting was the default treatment strategy. The primary endpoint was defined as the rate of cardiac death, myocardial infarction (MI) and clinically driven target lesion revascularization (TLR) in 12-month follow-up. Results The study population consisted of 95 patients (mean age: 66.8 ±9.8 years, 17.9% were females). A BiOSS LIM C stent was implanted in the left main (LM) in 53 (55.8%) cases. There were 25.2% of patients with NSTE-ACS, 33.7% with diabetes, 90.5% with hypertension, and 53.7% had previous MI. The device success rate was 100%. An additional regular drug-eluting stent was deployed in the side branch in 18.9% of cases. Proximal optimization technique and final kissing balloon (FKB) technique were used in 53.7% and 30.5% of cases, respectively. MI type 4a was registered in 4 (4.2%) cases. At 12 months the MACE rate was 9.5%, cardiac death 1.1%, MI 2.1% and clinically driven TLR 6.3%. All incidents, apart from one TLR, appeared in the LM subgroup. Conclusions Our registry might suggest that PCI using the BiOSS LIM C in coronary bifurcations is feasible and might be an option for percutaneous revascularization.https://www.archivesofmedicalscience.com/Twelve-month-clinical-results-from-the-new-cobalt-chromium-sirolimus-eluting-dedicated,111580,0,2.htmlcoronary bifurcationleft maindedicated bifurcation stentdrug-eluting stentsirolimus-eluting stent |
| spellingShingle | Robert J. Gil Adam Kern Tomasz Pawłowski Jacek Bil Twelve-month clinical results from the new cobalt-chromium sirolimus-eluting dedicated bifurcation stent BiOSS LIM C Registry Archives of Medical Science coronary bifurcation left main dedicated bifurcation stent drug-eluting stent sirolimus-eluting stent |
| title | Twelve-month clinical results from the new cobalt-chromium sirolimus-eluting dedicated bifurcation stent BiOSS LIM C Registry |
| title_full | Twelve-month clinical results from the new cobalt-chromium sirolimus-eluting dedicated bifurcation stent BiOSS LIM C Registry |
| title_fullStr | Twelve-month clinical results from the new cobalt-chromium sirolimus-eluting dedicated bifurcation stent BiOSS LIM C Registry |
| title_full_unstemmed | Twelve-month clinical results from the new cobalt-chromium sirolimus-eluting dedicated bifurcation stent BiOSS LIM C Registry |
| title_short | Twelve-month clinical results from the new cobalt-chromium sirolimus-eluting dedicated bifurcation stent BiOSS LIM C Registry |
| title_sort | twelve month clinical results from the new cobalt chromium sirolimus eluting dedicated bifurcation stent bioss lim c registry |
| topic | coronary bifurcation left main dedicated bifurcation stent drug-eluting stent sirolimus-eluting stent |
| url | https://www.archivesofmedicalscience.com/Twelve-month-clinical-results-from-the-new-cobalt-chromium-sirolimus-eluting-dedicated,111580,0,2.html |
| work_keys_str_mv | AT robertjgil twelvemonthclinicalresultsfromthenewcobaltchromiumsirolimuselutingdedicatedbifurcationstentbiosslimcregistry AT adamkern twelvemonthclinicalresultsfromthenewcobaltchromiumsirolimuselutingdedicatedbifurcationstentbiosslimcregistry AT tomaszpawłowski twelvemonthclinicalresultsfromthenewcobaltchromiumsirolimuselutingdedicatedbifurcationstentbiosslimcregistry AT jacekbil twelvemonthclinicalresultsfromthenewcobaltchromiumsirolimuselutingdedicatedbifurcationstentbiosslimcregistry |